Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations

March 26,2021

Feb. 26, 2021

Abstract: Multiple clinical studies are ongoing to assess whether existing vaccines may afford protection against SARS-CoV-2 infection through trained immunity. In this exploratory study, we analyze immunization records from 137,037 individuals who received SARS-CoV-2 PCR tests. We find that polio, Hemophilus influenzae type-B (HIB), measles-mumps-rubella (MMR), varicella, pneumococcal conjugate (PCV13), geriatric flu, and hepatitis A / hepatitis B (HepA-HepB) vaccines administered in the past 1, 2, and 5 years are associated with decreased SARS-CoV-2 infection rates, even after adjusting for geographic SARS-CoV-2 incidence and testing rates, demographics, comorbidities, and number of other vaccinations. Furthermore, age, race/ethnicity, and blood group stratified analyses reveal significantly lower SARS-CoV-2 rate among black individuals who have taken the PCV13 vaccine, with relative risk of 0.45 at the 5 year time horizon (n: 653, 95% CI: (0.32, 0.64), p-value: 6.9e-05). These findings suggest that additional pre-clinical and clinical studies are warranted to assess the protective effects of existing non-COVID-19 vaccines and explore underlying immunologic mechanisms. We note that the findings in this study are preliminary and are subject to change as more data becomes available and as further analysis is conducted.

Colin Pawlowski1+Arjun Puranik1+Hari Bandi1AJ Venkatakrishnan1Vineet Agarwal1Richard Kennedy2John C. O’Horo2Gregory J. Gores2, Amy W. Williams2John Halamka2Andrew D. Badley2Venky Soundararajan1
1nference, Cambridge, MA 02142, USA
2Mayo Clinic, Rochester, MN 55905, USA
+Joint First Author
Correspondence: Venky Soundararajan (venky@nference.net)
Correspondence: Andrew D Badley (badley.andrew@mayo.edu)




Media coverage:







Screen Shot 2021-04-01 at 8.47.50 AM


The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.